IL1RL2 and neoplasm: This significant induction of pro-tumorigenic genes highlights the necessity to consider signalling by the IL-36R+ tumour cells when considering IL-36 adjuvant therapies, as well as consideration of the importance of blocking this signalling pathway to reduce the pro-tumorigenic effects of these chemokines.